Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onapristone and Anastrozole in Refractory Hormone Receptor Positive Endometrial Cancer
NCT04719273Phase 2Completed
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2021
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of onapristone extended release in endometrial cancer (EC), sponsored by Thomas Jefferson University. Started Jan 2021; status: completed.
02
Drugs
onapristone extended release
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04719273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04719273.